Damora Therapeutics, Inc. DMRA
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each USD of equity lost 164 cents this year.
The 7-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue $B | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Operating income $B | −0.2 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | 0.0 |
| EBITDA $B | −0.2 | −0.0 | −0.0 | −0.1 | −0.1 | ◌ | ◌ |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.2 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 |
| Free cash flow $B | ◌ | ◌ | ◌ | −0.0 | −0.1 | ◌ | ◌ |
| EPS, diluted $ | 3.98 | −18.53 | −36.08 | −2.43 | −2.05 | −7.62 | −161.82 |
| Dividend / sh $ | 0.00 | 0.00 | ◌ | ◌ | 0.00 | 0.00 | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — |
| ROE % | −163.8 | −89.0 | −81.5 | −68.9 | −36.6 | — | — |
| Shares out B | 0.00 | 0.00 | 0.03 | 0.03 | 0.03 | 0.03 | 0.00 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 6 of the 7 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 12 checks were skipped: EPS is not tagged before 2019.